Evidence map›Paper›PMID 28885584›Full record

ArticleInternational journal of molecular sciences2017

Morphological Evaluation of Tumor-Infiltrating Lymphocytes (TILs) to Investigate Invasive Breast Cancer Immunogenicity, Reveal Lymphocytic Networks and Help Relapse Prediction: A Retrospective Study.

Gloria Romagnoli, Meike Wiedermann, Friederike Hübner, Antonia Wenners, Micaela Mathiak, Christoph Röcken, Nicolai Maass, Wolfram Klapper, Ibrahim Alkatout

Open access · goldAbstract read
In one paragraph

Article in International journal of molecular sciences, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
16citing papers in PubMed, 1 pooled it
0.8field-weighted citation impact, top 30% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

16 citing papers in PubMed, 1 synthesis or guideline pooled it, 28 citations in OpenAlex.

  1. Imaging of tumour response to immunotherapy.European radiology experimental · 2020
    Pooled it
  2. Unbiased avidity-based isolation of antigen-specific T cells.Journal for immunotherapy of cancer · 2026
    Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Observational
  16. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 3 institutions in 2 countries.

Gloria RomagnoliSchool of Life & Health Sciences, Aston Brain Centre, Aston University, Birmingham B4 7ET, UK. g.romagnoli@aston.ac.uk.ORCID 0000-0001-5337-1727
Meike WiedermannDepartment of Radiology and Neuroradiology, Klinikum Dortmund, 44137 Dortmund, Germany. meikewiedermann@googlemail.com.
Friederike HübnerDepartment of Gynecology and Obstetrics, University Hospitals Schleswig-Holstein, 24105 Campus Kiel, Germany. rike_huebner@gmx.de.
Antonia WennersDepartment of Gynecology and Obstetrics, University Hospitals Schleswig-Holstein, 24105 Campus Kiel, Germany. Antonia.Wenners@gmx.de.
Micaela MathiakDepartment of Pathology, General Pathology and Hematopathology, University Hospitals Schleswig-Holstein, 24105 Campus Kiel, Germany. Micaela.Mathiak@uksh.de.
Christoph RöckenDepartment of Pathology, General Pathology and Hematopathology, University Hospitals Schleswig-Holstein, 24105 Campus Kiel, Germany. christoph.roecken@uksh.de.
Nicolai MaassDepartment of Gynecology and Obstetrics, University Hospitals Schleswig-Holstein, 24105 Campus Kiel, Germany. Nicolai.Maass@uksh.de.
Wolfram KlapperDepartment of Pathology, General Pathology and Hematopathology, University Hospitals Schleswig-Holstein, 24105 Campus Kiel, Germany. wklapper@path.uni-kiel.de.
Ibrahim AlkatoutDepartment of Gynecology and Obstetrics, University Hospitals Schleswig-Holstein, 24105 Campus Kiel, Germany. ibrahim.alkatout@uksh.de.
University Hospital Schleswig-Holstein · DEAston University · GBKlinikum Dortmund · DE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Tumor-infiltrating lymphocytes (TILs) in breast cancer are a key representative of the tumor immune microenvironment and have been shown to provide prognostic and predictive biomarkers. The extent of lymphocytic infiltration in tumor tissues can be assessed by evaluating hematoxylin and eosin (H&E)-stained tumor sections. We investigated tissue microarrays of 31 invasive breast cancer patients, looking at quantity and topological distribution of CD3+, CD8+, CD20+, Ki67+, FoxP3+ TILs and CD3+/FoxP3+, CD8+/FoxP3+ cell ratios. We separately evaluated TILs at the invasive edge and at the center of the tumor, to find any clinical implications of tumor heterogeneity. No statistically significant difference was found in quantity and distribution of both TIL subsets and TIL ratios, by comparing patients who suffered from a local or distant recurrence of the tumor (relapse group: 13 patients) with patients not showing cancer relapse (non-relapse group: 18 patients). In the whole sample, we observed three main statistically significant positive correlations: (1) between CD3+ and CD8+ T-cells; (2) between FoxP3+ and Ki67+ lymphocyte infiltration; (3) between CD3+/FoxP3+ cell ratio (C3FR) and CD8+/FoxP3+ cell ratio (C8FR). Tumor heterogeneity and stronger positive TIL associations were found in the non-relapse group, where both CD3-CD8 and FoxP3-Ki67 inter-correlations were found to be significant at the center of the tumor, while the correlation between C3FR and C8FR was significant at the invasive edge. No correlations between TIL subsets were detected in the relapse group. Our findings suggest the existence of stronger inter-subtype lymphocytic networks in invasive breast cancer not showing recurrence. Further evaluations of clinical and topological correlations between and within TIL subsets are needed, in addition to the assessment of TIL quantification and distribution, in order to follow up on whether morphological evaluation of TILs might reveal the underlying lymphocytic functional connectivity and help relapse prediction.

Indexed as

BiomarkersBreast NeoplasmsCell CommunicationFemaleHumansImmunohistochemistryImmunophenotypingLymphocyte CountLymphocytes, Tumor-InfiltratingNeoplasm InvasivenessNeoplasm Recurrence, LocalPrognosisRetrospective StudiesT-Lymphocyte SubsetsTumor MicroenvironmentBiomarkersbreast cancerCD3CD3/FoxP3 ratioCD8CD8/FoxP3 ratioFoxP3regulatory T cells (Tregs)tumor heterogeneitytumor immunogenicitytumor-infiltrating lymphocytes (TILs)

Identifiers

PMID28885584
PMCPMC5618585
OpenAlexW2752397604

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.